Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26 ! 👏
Ph3, n=653 cis-eligible MIBC: neoadj GC + nivo → adj nivo vs GC alone.
Median f/u 54.5 mo.
🔹 pCR 39.1% vs 29.6%: not dig
🔹 EFS HR 0.94: co-primaries not met
🔹 OS HR 0.88
👉Negative trial, but the ctDNA data are a key message: detectable ctDNA at baseline and after NAC strongly prognostic for worse EFS & OS.
Selecting patients by ctDNA, rather than adding IO for all, is where the field is heading!
Great to see this build on our Ph2 BLASST-1. Despite the negative result, it's very practice-informing.

Proud to be a part of this effort!
@CleClinicMD @caseccc @CleClinicUro @sonpavde @MattGalsky @MichvdHeijden @Uromigos @Annals_Oncology @tompowles1